This phase Ib study assessed the safety and compatibility of indirect oregovomab immunization and Toll-like-receptor-3 stimulation with immune adjuvant Hiltonol® and induced clinically relevant cancer antigen-125-specific anti-tumor immunity in heavily pretreated patients with platinum-resistant ovarian cancer. This evidence concerns the gene TLR3 and neoplasm.